Pluri Inc.
As of Oct 22, 2026, Pluri is in Stage 4, the downtrend phase, now in week 25 (since Apr 29, 2026). It closed at $1.01, 77.3% below its 52-week high and below its 200-day average, which is falling.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is PLUR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PLUR among Biotechnology446th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …446 | PLUR | Stage 4 · wk 25 | 13 | −4.7% |
Pluri: quick answers
What stage is Pluri in?
As of Oct 22, 2026, Pluri (PLUR) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 29, 2026 and is in week 25. What the four stages mean
Is Pluri in an uptrend?
No. Pluri is in a Stage 4 downtrend. It trades 58.6% below its 200-day average, which is falling.
How far is Pluri from its 52-week high?
Pluri closed at $1.01 on Oct 22, 2026, 77.3% below its 52-week high of $4.45. Its 52-week low is $0.85.
How has Pluri performed over the past year?
As of Oct 22, 2026, Pluri is down 75.3% over the past year and down 66.2% so far in 2026.
Which sector and industry is Pluri in?
Pluri is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.